Shanghai Chuangli Group (603012.SH) issued a profit warning, with the estimated net profit for 2024 expected to be between 190 million yuan and 228 million yuan, a decrease of 43.23% to 52.69%.
Chuangli Group (603012.SH) issued a performance forecast announcement for the year 2024, estimating that it will achieve...
Shanghai Chuangli Group (603012.SH) released its performance forecast for the year 2024, expecting a net profit attributable to the owners of the parent company of 1.9 billion to 2.28 billion yuan, a year-on-year decrease of 43.23% to 52.69%.
The main reasons for the change in the company's performance during the reporting period are: (1) a decline in coal prices, intensifying market competition in the coal machinery industry, resulting in a decrease in the prices of orders obtained by the company and a decrease in gross profit margin; (2) an increase in accounts receivable and aging of some accounts receivable, leading to an increase in credit impairment losses provisioned according to relevant credit policies; (3) a decrease in investment income, mainly due to the disposal of equity in subsidiary companies in 2023 that generated investment income.
Related Articles

Bank of China (03988) has completed the issuance of 50 billion yuan of subordinate capital bonds.

Goldman Sachs Group, Inc.: Bullish on the aerospace sector's "disruptive" opportunities, Rocket Lab (RKLB.US) sets a new record for government orders, with a target price of $47.

Livzon Pharmaceutical Group Inc. (000513.SZ): Application for market approval of Lepikacumab injection received.
Bank of China (03988) has completed the issuance of 50 billion yuan of subordinate capital bonds.

Goldman Sachs Group, Inc.: Bullish on the aerospace sector's "disruptive" opportunities, Rocket Lab (RKLB.US) sets a new record for government orders, with a target price of $47.

Livzon Pharmaceutical Group Inc. (000513.SZ): Application for market approval of Lepikacumab injection received.

RECOMMEND





